In the past two decades, we have witnessed the discovery and development of many potent
and efficacious proteolysis-targeting chimera (PROTAC) degraders, with several in phase I/II …

Obesity is known to have important roles in driving prostate cancer aggressiveness and
increased mortality. Multiple mechanisms have been postulated for these clinical …

Treatment of advanced metastatic castration-resistant prostate cancer after failure of
approved therapy options remains challenging. Prostate-specific membrane antigen (PSMA) …

Purpose Preliminary data from retrospective analyses and recent data from large
randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) …

Although second-line antiandrogen therapy (SAT) is the standard of care in men with
castration-resistant prostate cancer (CRPC), resistance inevitably occurs. One major …

The functional consequences of genetic variants within 5'untranslated regions (UTRs) on a
genome-wide scale are poorly understood in disease. Here we develop a high-throughput …

The androgen receptor (AR) plays a predominant role in prostate cancer (PCa) pathology. It
consists of an N-terminal domain (NTD), a DNA-binding domain (DBD), a hinge region (HR) …

Introduction Metastatic castrate resistant prostate cancer (mCPRC) remains an aggressive
form of prostate cancer that no longer responds to traditional hormonal treatment alone …

Prostate cancer (PC) is the most frequently diagnosed malignancy and a leading cause of
cancer deaths in US men. Many PC cases metastasize and develop resistance to systemic …

Androgen receptor (AR) is an effective therapeutic target for the treatment of prostate cancer.
We report herein the design, synthesis, and biological evaluation of highly effective …